Medisonal has been acquired by TTS Pharma
TTS Pharma was formed in 2012 to acquire and develop proprietary drug delivery technologies, TTS Pharma has established a vertically integrated supply chain developing EU compliant Cannabinoid products that meet all regulatory and legal requirements for the UK. By applying pharmaceutical logic to deliver consistent quality throughout our supply chain, our ‘full-service’ offering ensures regulatory requirements are met. Our transparency with authorities in the UK enables TTS Pharma to provide the stability and long-term assurance any business demands. TTS Pharma’s bulk CBD ingredient is subject to thorough testing processes that ensure its safety, quality, and consistency. Each batch undergoes meticulous analysis by accredited third-party laboratories, adhering to industry standards and regulatory guidelines. With a portfolio of 860 skus across 12 product formats, TTS Pharma is well positioned to support a diverse and growing customer base with high quality, fully compliant CBD ingredients.
We’re excited that Medisonal has joined the TTS Pharma family. This partnership marks an important step forward in expanding our expertise and strengthening the support we provide to patients. Together with TTS Pharma, we look forward to building on our shared commitment to improving patient outcomes, delivering innovative solutions, and ensuring the highest standards of care. We’re confident this collaboration will bring even greater value to the patients and communities we serve, and we’re eager to begin this next chapter together.







